PET/CT scans with the investigational radiopharmaceutical gallium-68 (Ga-68) DOTATOC homed in on neuroendocrine tumors and changed patient management in a number of cases, according to a study presented at this week’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. {read more here}